These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11177688)

  • 21. Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients.
    Lee S; Kim IH; Kim SH; Kim SW; Lee SO; Lee ST; Kim DG; Lee CS; Choi CS; Cho EY; Kim HC
    Intervirology; 2010; 53(3):146-53. PubMed ID: 20068348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Durability of sustained virologic response in chronic hepatitis C: analysis of factors related to relapse after sustained virologic response with peginterferon plus ribavirin combination therapy].
    Lee JE; Yoon NR; Kim JD; Song MJ; Kwon JH; Bae SH; Choi JY; Jeong SW; Yoon SK
    Korean J Gastroenterol; 2011 Mar; 57(3):173-9. PubMed ID: 21519165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    Yenice N; Mehtap O; Gümrah M; Arican N
    Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
    Nachnani JS; Rao GA; Bulchandani D; Pandya PK; Alba LM
    Ann Hematol; 2010 Feb; 89(2):121-5. PubMed ID: 19565241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study.
    Borgia G; Gentile I; Fortunato G; Borrelli F; Borelli S; de Caterina M; Di Taranto MD; Simone M; Borgia F; Viola C; Reynaud L; Cerini R; Sacchetti L
    Liver Int; 2009 Feb; 29(2):248-52. PubMed ID: 18662278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients.
    Langlet P; D'Heygere F; Henrion J; Adler M; Delwaide J; Van Vlierberghe H; Mulkay JP; Lasser L; Brenard R; Horsmans Y; Michielsen P; Laureys A; Nevens F
    Aliment Pharmacol Ther; 2009 Aug; 30(4):352-63. PubMed ID: 19485978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y; Kanto H; Itoh M
    J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection.
    Lin TY; Yeh ML; Huang CI; Chen YL; Dai CY; Huang JF; Lin ZY; Chen SC; Huang CF; Yu ML; Chuang WL
    Kaohsiung J Med Sci; 2017 Jun; 33(6):284-289. PubMed ID: 28601232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies.
    Fabrizi F; Dixit V; Messa P; Martin P
    J Viral Hepat; 2014 Oct; 21(10):681-9. PubMed ID: 25040244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
    Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antiviral/immunomodulatory combination therapy: pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection].
    Delić D; Mitrović N; Popović N; Urošević A; Pešiċ I; Simonoviċ J
    Srp Arh Celok Lek; 2012; 140(9-10):612-8. PubMed ID: 23289278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The sustained virologic response of nonresponder hepatitis C virus patients with retreatment.
    Akhan SC; Gurel E; Sayan M
    Indian J Pathol Microbiol; 2011; 54(1):81-4. PubMed ID: 21393883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A; Tornai I; Szalay F
    Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical value of pegylated interferon-α plus ribavirin-based therapy in antiviral treatment of chronic hepatitis C in China].
    Zhu F; Zhang QY; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):173-174. PubMed ID: 29807402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy.
    Levent G; Ali A; Ahmet A; Polat EC; Aytaç C; Ayşe E; Ahmet S
    J Transl Med; 2006 Jun; 4():25. PubMed ID: 16787540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4.
    Urquijo JJ; Diago M; Boadas J; Planas R; Solá R; Del Olmo JA; Crespo J; Erdozaín JC; Antón MD; Arocena C; Suarez D; Giné J; Barrera JM; Gracia-Samaniego J; Perez R; Dalmau B; Montoro M
    Ann Hepatol; 2013; 12(1):30-5. PubMed ID: 23293191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future.
    Ferenci P
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):157-74. PubMed ID: 16557187
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.